Recruiting
Phase 1
Phase 2

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Sponsor:

Hoffmann-La Roche

Code:

NCT05908786

Conditions

Carcinoma, Hepatocellular

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Bevacizumab

Tiragolumab

Tobemstomig

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information